About Us
Visionary Innovation to Deliver Breakthrough Therapies
Our Story
Oculis is a global biopharmaceutical company focused on innovation addressing neuro-ophthalmic and ophthalmic conditions with significant unmet medical needs.
The OPTIREACH® solubilizing formulation technology was developed by two Icelandic Professors Einar Stefánsson, and Thorsteinn Loftsson. This groundbreaking innovation was designed to enable eye drops to effectively reach the back of the eye and was leveraged to develop Oculis’ first product candidate, OCS-01 eye drops for diabetic macular edema. Since its inception, the Oculis team has grown the company into a leader in neuro-ophthalmology and ophthalmology by adding Privosegtor, a novel neuroprotective candidate with potential broad applicability in neuro-ophthalmology and neurology indication, and Licaminlimab, an anti-TNFα eye drop to drive precision medicine in dry eye disease, to its highly differentiated late-stage clinical pipeline.
At the heart of our visionary innovation is a bold commitment to rethink what’s possible for patients. Guided by unmet medical needs and grounded in cutting-edge science, we are in pursuit of health breakthroughs that go beyond incremental change and challenge convention.
By redefining how we understand complex diseases and with a relentless focus on highly differentiated development opportunities, we aim to transform treatment approaches and bring a lasting impact to the lives of patients.
Our History
OPTIREACH® animal proof-of-concept and exploratory studies in humans were completed.
Oculis was incorporated in Switzerland supported by private investors to further develop its first clinical-stage asset, OCS-01, and broaden its portfolio.
Licaminlimab, an anti-TNFα eye drop for ocular inflammation disorders like dry eye disease (DED), was added to Oculis’ pipeline from Novartis
OCS-01 positive Phase 2 trial results in diabetic macular edema (DME): Efficacy endpoints of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were met.
OCS-01 positive Phase 2 SKYGGN trial results for the treatment of inflammation and pain following cataract surgery: primary endpoint and key secondary endpoints were met with once daily dosing.
OCS-01 was successfully advanced to Phase 3 in DME following an affirming end-of-phase 2 meeting with the U.S. FDA.
OCS-01 DIAMOND Phase 3 program in DME was initiated.
Privosegtor, a potential neuroprotective candidate for the treatment of acute optic neuritis was added to Oculis’ pipeline from Accure Therapeutics.
OCS-01 OPTIMIZE Phase 3 trial for the treatment of inflammation and pain following cataract surgery with once daily administration was initiated.
Oculis was publicly listed on U.S. NASDAQ Global Market enabling significant fundraising to fuel the advancement of its highly differentiated late-stage pipeline.
OCS-01 positive DIAMOND Stage 1 Phase 3 trial results in DME were achieved.
OCS-01 positive OPTIMIZE Phase 3 trial results with once daily regimen for the treatment of inflammation and pain following cataract surgery were achieved.
Second 52-week Phase 3 trial of OCS-01 eye drops in DME (DIAMOND-2) was initiated.
Oculis became a dually listed company with a second public listing on NASDAQ Iceland Main Market.
Licaminlimab positive RELIEF Phase 2b trial results in signs of DED were achieved, showing potential for precision medicine.
Privosegtor groundbreaking ACUITY Phase 2 trial results in acute optic neuritis, were achieved, showing potential as a neuroprotective candidate
OCS-01 completion of enrollment in DIAMOND Phase 3 program in DME with over 800 patients randomized across both trials.
Privosegtor PIONEER Program debuted and is in motion for acute optic neuritis (AON)